{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:40:30Z","timestamp":1794775230983,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Diabetes &amp; Endocrinology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/s2213-8587(19)30313-4","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T18:37:24Z","timestamp":1568831844000},"page":"855-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanaska","family":"Elenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Auchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza B","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemyslaw","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M K","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2213-8587(19)30313-4_bib1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(19)30313-4_bib2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1517\/14656566.2015.1061995","article-title":"Cushing's syndrome: an update on current pharmacotherapy and future directions","volume":"16","author":"Creemers","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/S2213-8587(19)30313-4_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1210\/jc.2018-02524","article-title":"Overall and disease-specific mortality in patients with Cushing's disease: a Swedish nationwide study","volume":"104","author":"Ragnarsson","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(19)30313-4_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing's disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/S2213-8587(19)30313-4_bib6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(19)30313-4_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ecl.2014.10.006","article-title":"Medical treatment of Cushing disease: new targets, new hope","volume":"44","author":"Fleseriu","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/S2213-8587(19)30313-4_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing's syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib9","series-title":"Ketoconazole HRA 200 mg tablets","year":"2015"},{"key":"10.1016\/S2213-8587(19)30313-4_bib10","series-title":"Ketoconazole tablets USP, 200 mg [package insert]","year":"2017"},{"key":"10.1016\/S2213-8587(19)30313-4_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"2 suppl","key":"10.1016\/S2213-8587(19)30313-4_bib12","article-title":"2S,4R-ketoconazole is the relevant enantiomer of ketoconazole for cortisol synthesis inhibition: steroidogenic P450s inhibition involves multiple mechanisms","volume":"39","author":"Auchus","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/S2213-8587(19)30313-4_bib13","series-title":"Ketoconazole HRA: assessment report","year":"2014"},{"key":"10.1016\/S2213-8587(19)30313-4_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/EJE-17-0886","article-title":"Hepatic safety of ketoconazole in Cushing's syndrome: results of a compassionate use programme in France","volume":"178","author":"Young","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2125.2011.04093.x","article-title":"Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study","volume":"73","author":"Boyce","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib16","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/CIRCULATIONAHA.109.894725","article-title":"Drug-induced arrhythmia","volume":"122","author":"Heist","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/S2213-8587(19)30313-4_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/S2213-8587(19)30313-4_bib18","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.39.8.1671","article-title":"Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole","volume":"39","author":"Chin","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S2213-8587(19)30313-4_bib19","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.clinthera.2008.05.021","article-title":"Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus","volume":"30","author":"Schwartz","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/S2213-8587(19)30313-4_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0762","article-title":"Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire","volume":"158","author":"Webb","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib21","series-title":"Beck Depression Inventory","author":"Beck","year":"1996"},{"key":"10.1016\/S2213-8587(19)30313-4_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0022-4731(82)90038-3","article-title":"Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature","volume":"16","author":"S\u00f6derg\u00e5rd","year":"1982","journal-title":"J Steroid Biochem"},{"key":"10.1016\/S2213-8587(19)30313-4_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","article-title":"Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study","volume":"4","author":"Clayton","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib24","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/EJE-14-0556","article-title":"Management of endocrine disease: mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis","volume":"172","author":"van Haalen","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib25","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2011-2813","article-title":"Impact of mifepristone, a glucocorticoid\/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function","volume":"97","author":"Page","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(19)30313-4_bib26","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(19)30313-4_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(19)30313-4_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0022-3565(24)37646-3","article-title":"Blockade of HERG and Kv1.5 by ketoconazole","volume":"286","author":"Dumaine","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S2213-8587(19)30313-4_bib30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bjp.0707537","article-title":"Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome","volume":"153","author":"Takemasa","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/S2213-8587(19)30313-4_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001615","article-title":"Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil","volume":"4","author":"Vicente","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/S2213-8587(19)30313-4_bib32","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4158\/EP171787.OR","article-title":"Biochemical control during long-term follow-up of 230 adult patients with Cushing disease: a multicenter retrospective study","volume":"23","author":"Geer","year":"2017","journal-title":"Endocr Pract"}],"container-title":["The Lancet Diabetes &amp; Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858719303134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858719303134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:07:18Z","timestamp":1761991638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213858719303134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2213858719303134"],"URL":"https:\/\/doi.org\/10.1016\/s2213-8587(19)30313-4","relation":{},"ISSN":["2213-8587"],"issn-type":[{"value":"2213-8587","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Diabetes & Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(19)30313-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(19)30312-2","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}